C76 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions
| Event Time: | Sunday May 5, 2019 3:30 pm to 5:30 pm |
| Topic(s): | Aging, Dementia, Cognitive, and Behavioral Neurology, Advanced Practice Provider |
| Director(s): | Michael Geschwind MD, PhD, FAAN |
| Description: | Rapidly progressive dementia (RPD) can be challenging to diagnose. The differential diagnosis is broad and includes many potentially reversible conditions. As many RPD are treatable if addressed early, quick diagnosis is important. Through presentation of common and challenging cases, faculty will review the differential diagnosis of RPD, the approach, and management strategies. This session will focus on prion and antibody-mediated disorders. At the conclusion of this program, attendees are invited to "continue the conversation" by engaging in small group conversation with the director and faculty. This program complements: Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases, but covers independent topics. |
| Completion Message: | Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge |
| Start/End Time | Title | Faculty |
|---|---|---|
| 3:30 PM - 3:35 PM | Introduction | Michael D. Geschwind MD, PhD, FAAN |
| 3:35 PM - 4:25 PM | Infections as Rapidly Progressive Dementia | Allen J. Aksamit MD, FAAN |
| 4:25 PM - 5:15 PM | Autoimmune Causes of Rapidly Progressive Dementia | Jeffrey Marc Gelfand MD, MAS, FAAN |
| 5:15 PM - 5:30 PM | Questions and Answers | Faculty |
| 5:30 PM - 6:00 PM | Continuing the Conversation | Faculty |
| Speaker | Disclosure |
|---|---|
| Allen J. Aksamit, Jr., MD, FAAN | Dr. Aksamit has nothing to disclose. |
| Jeffrey Marc Gelfand, MD, MAS, FAAN | Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Alexion, Alkem Laboratories Ltd., Accord Healthcare Inc, Apotex Corp., Apotex Inc., Teva Pharmaceuticals USA, Inc., Roxane Laboratories Inc., Mylan Pharmaecuticals Inc., Merck, United States Department of Health and Human Services, and United States Department of Justice Vaccine Injury Compensation Program. Dr. Gelfand has received personal compensation in an editorial capacity for Dynamed Plus, and Neurology Neuroimmunology and Neuroinflammation. Dr. Gelfand has received research support from Genentech and MedDay. |
| Michael D. Geschwind, MD, PhD, FAAN | Dr. Geschwind has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adept Field Consulting, 3M Communications, Grand Rounds Inc., Best Doctors Inc., BPP Inc, and Anderson Boutwell Traylor. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 11:45 AM-12:45 PM |
|
Friday Grand Finale: Neuroimaging
|
| 1:00 PM-3:00 PM |
|
C252 -
Update in Aging and Dementia
Gil Rabinovici MD |
| 3:30 PM-4:30 PM |
|
C255 -
Education Blitz: Normal Pressure Hydrocephalus
Neill Graff-Radford MD, FAAN |